Hitchins R N, Harman D H, Davey R A, Bell D R
Department of Clinical Oncology, Royal North Shore Hospital, St Leonards, N.S.W., Australia.
Eur J Cancer Clin Oncol. 1988 Mar;24(3):449-54. doi: 10.1016/s0277-5379(98)90015-3.
The multidrug resistance (NDR) phenotype describes a pattern of cross-resistance to unrelated compounds observed in mammalian cell lines selected in vitro for resistance to a single agent. Overexpression of a 170,000 dalton cell membrane glycoprotein (P-glycoprotein) is associated consistently with this phenotype in these cell lines. Recently, several human tumours have been shown to contain P-glycoprotein and expression was greatest in tumours exhibiting clinical drug resistance. To explore further the significance of P-glycoprotein, we examined normal human tissues obtained at autopsy by polyacrylamide gel electrophoresis and immunoblotting using a monoclonal antibody directed against P-glycoprotein. We showed expression of P-glycoprotein in normal liver and small bowel mucosa but not in other organs examined. This suggests there may be significant expression of P-glycoprotein in certain normal human tissues and any plan to exploit P-glycoprotein clinically must take these findings into account.
多药耐药(NDR)表型描述了在体外选择对单一药物耐药的哺乳动物细胞系中观察到的对不相关化合物的交叉耐药模式。在这些细胞系中,一种170,000道尔顿的细胞膜糖蛋白(P-糖蛋白)的过表达始终与这种表型相关。最近,已证明几种人类肿瘤含有P-糖蛋白,并且在表现出临床耐药性的肿瘤中表达最高。为了进一步探讨P-糖蛋白的意义,我们通过聚丙烯酰胺凝胶电泳和使用针对P-糖蛋白的单克隆抗体进行免疫印迹,检查了尸检时获得的正常人体组织。我们发现P-糖蛋白在正常肝脏和小肠黏膜中有表达,但在所检查的其他器官中没有。这表明在某些正常人体组织中可能存在P-糖蛋白的显著表达,任何临床利用P-糖蛋白的计划都必须考虑到这些发现。